EBS
Emergent BioSolutions Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -9.1% ·
share flow +3.7% ·
net new positions -10.0%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 71.56K | $475,495 | n/a | n/a |
| Q2 2026 | 77 | 0 | 32.10M | $268.98M | +5 | −5 |
| Q1 2026 | 79 | +5 | 31.51M | $261.75M | +9 | −4 |
| Q4 2025 | 74 | 0 | 30.66M | $378.98M | n/a | n/a |
| Q3 2025 | 18 | +2 | 16.19M | $142.77M | +2 | n/a |
| Q2 2025 | 13 | 0 | 14.86M | $94.78M | n/a | n/a |
| Q1 2025 | 10 | -1 | 7.86M | $38.21M | n/a | −1 |
| Q4 2024 | 11 | +1 | 7.58M | $72.46M | +1 | n/a |
| Q3 2024 | 9 | 0 | 6.09M | $50.89M | +1 | −1 |
| Q2 2024 | 9 | n/a | 4.41M | $30.11M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 2.50M | +68.9% | $12.16M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 1.71M | -12.9% | $8.31M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Marshall Wace ✦ | 1.16M | -12.8% | $5.63M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 4 | Renaissance Technologies ✦ | 760.25K | +14.2% | $3.69M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 612.29K | +3.6% | $2.98M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 396.80K | -53.1% | $1.93M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 294.92K | +95.5% | $1.43M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | D. E. Shaw & Co. ✦ | 272.27K | -28.9% | $1.32M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 9 | Wellington Management ✦ | 142.97K | +5.6% | $694,815 | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 10 | T. Rowe Price ✦ | 11.80K | 0.0% | $58,000 | 0.0% | Held | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Gotham Asset Management | $199,880 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 187 holders, 43.00M shares, $335.12M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 17.80K sh · $126,202
Officer · 3.00K sh · $19,590
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology